|
1
|
Brugnaro P, Morelli E, Cattelan F,
Petrucci A, Panese S, Eseme F, Cavinato F, Barelli A and Raise E:
Non-acquired immunodeficiency syndrome defining malignancies among
human immunodeficiency virus-positive subjects: Epidemiology and
outcome after two decades of HAART era. World J Virol. 4:209–218.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Robbins HA, Pfeiffer RM, Shiels MS, Li J,
Hall HI and Engels EA: Excess cancers among HIV-infected people in
the United States. J Natl Cancer Inst. 107:dju5032015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rubinstein PG, Aboulafia DM and Zloza A:
Malignancies in HIV/AIDS: From epidemiology to therapeutic
challenges. AIDS. 28:453–465. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yotsumoto M, Hagiwara S, Ajisawa A, Tanuma
J, Uehira T, Nagai H, Fujikawa Y, Maeda S, Kitano K, Arima N, et
al: Clinical characteristics of human immunodeficiency
virus-associated Hodgkin lymphoma patients in Japan. Int J Hematol.
96:247–253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Said JW: Immunodeficiency-related Hodgkin
lymphoma and its mimics. Adv Anat Pathol. 14:189–194. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Flavell KJ and Murray PG: Hodgkin's
disease and the Epstein-Barr virus. Mol Pathol. 53:262–269. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dolcetti R, Boiocchi M, Gloghini A and
Carbone A: Pathogenetic and histogenetic features of HIV-associated
Hodgkin's disease. Eur J Cancer. 37:1276–1287. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carbone A, Gloghini A, Serraino D and
Spina M: HIV-associated Hodgkin lymphoma. Curr Opin HIV AIDS.
4:3–10. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee JH, Kim Y, Choi JW and Kim YS:
Prevalence and prognostic significance of Epstein-Barr virus
infection an classical Hodgkin's lymphoma: A meta-analysis. Arch
Med Res. 45:417–431. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Keegan TH, Glaser SL, Clarke CA, Gulley
ML, Craig FE, Digiuseppe JA, Dorfman RF, Mann RB and Ambinder RF:
Epstein-Barr virus as a marker of survival after Hodgkin's
lymphoma: A population-based study. J Clin Oncol. 23:7604–7613.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jarret RF, Stark GL, White J, Angus B,
Alexander FE, Krajewski AS, Freeland J, Taylor GM and Taylor PR:
Scotland and Newcastle Epidemiology of Hodgkin Disease Study Group:
Scotland and newcastle epidemiology of hodgkin disease study group.
Impact of tumor Epstein-Barr virus status on presenting features
and outcome in age-defined subgroups of patients with classic
Hodgkin lymphoma: A population-based study. Blood. 106:2444–2451.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koh YW, Yoon DH, Suh C and Huh J: Impact
of the Epstein-Barr virus positivity on Hodgkin's lymphoma in a
large cohort from a single institute in Korea. Ann Hematol.
9:1403–1412. 2012. View Article : Google Scholar
|
|
13
|
Sorigué M, García O, Tapia G, Baptista MJ,
Moreno M, Mate JL, Sancho JM, Feliu E, Ribera JM and Navarro JT:
HIV-infection has no prognostic impact on advanced-stage Hodgkin
lymphoma. AIDS. 31:1445–1449. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hagiwara S, Yotsumoto M, Odawara T,
Ajisawa A, Uehira T, Nagai H, Tanuma J and Okada S:
Non-AIDS-defining hematological malignancies in HIV-infected
patients: An epidemiological study in Japan. AIDS. 27:279–283.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheson BD, Horning SJ, Coiffer B, Shipp
MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A,
Hagenbeek A, et al: Report of an international workshop to
standardize response criteria for non-Hodgkin's lymphomas. NCI
Sponsored International Working Group. J Clin Oncol. 17:12441999.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hasenclever D and Diehl V: A prognostic
score for advanced Hodgkin's disease. International prognostic
factors project on advanced hodgkin's disease. N Engl J Med.
339:1506–1514. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morton LM, Wang SS, Devesa SS, Hartge P,
Weisenburger DD and Linet MS: Lymphoma incidence patterns by WHO
subtype in the United States, 1992–2001. Blood. 107:265–276. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shimabukuro-Vornhagen A, Haver H, Engert
A, Balleisen L, Majunke P, Heil G, Eich HT, Stein H, Diehl V and
Josting A: Lymphocyte-rich classical Hodgkin's lymphoma: Clinical
presentation and treatment outcome in 100 patients treated within
German Hodgkin's Study Group trials. J Clin Oncol. 23:5739–3745.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shiels MS, Pfeiffer RM, Gail MH, Hall HI,
Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, Goedert JJ
and Engels EA: Cancer burden in the HIV-infected population in the
United States. J Natl Cancer Inst. 103:753–762. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hoffman C, Chow KU, Wolf E, Faetkenheuer
G, Stellbrink HJ, van Lunzen J, Jaeger H, Stoehr A, Plettenberg A,
Wasmuth JC, et al: Strong impact of highly active antiretroviral
therapy on survival in patients with human immunodeficiency
virus-associated Hodgkin's disease. Br J Haematol. 125:455–462.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nguyen ML, Farrell KJ and Gunthel CJ:
Non-AIDS-defining malignancies in patients with HIV infection in
the HAART era. Curr Infect Dis Rep. 12:46–55. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Spina M, Carbone A, Gloghini A, Serraino
D, Berretta M and Tirelli U: Hodgkin's disease in patients with HIV
infection. Adv Hematol. 2011:4026822011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Glaser SL, Lin RJ, Stewart SL, Ambinder
RF, Jarrett RF, Brousset P, Pallesen G, Gulley ML, Khan G, O'Grady
J, et al: Epstein-Barr virus-associated Hodgkin's disease:
Epidemiologic characteristics in international data. Int J Cancer.
70:375–382. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Petrovas C, Casazza JP, Brenchley JM,
Price DA, Gostick E, Adams WC, Precopio ML, Schacker T, Roederer M,
Douek DC and Koup RA: PD-1 is a regulator of virus-specific
CD8+ T cell survival in HIV infection. J Exp Med.
203:2281–2292. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Porochis F and Kaufmann DE: Role of PD-1
in HIV pathogenesis and as target for therapy. Curr HIV/AIDS Rep.
9:81–90. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
The World Health Organization
classification of malignant lymphomas in Japan: Incidence of
recently recognized entities. Lymphoma Study Group of Japanese
Pathologists. Pathl Int. 50:696–702. 2000. View Article : Google Scholar
|
